StockNews.com cut shares of Incyte (NASDAQ:INCY – Free Report) from a strong-buy rating to a buy rating in a report released on Thursday. A number of other research firms also recently commented on INCY. Bank of America dropped their price target on shares of Incyte from $69.00 to $67.00 and set a neutral rating on […]
StockNews.com lowered shares of Incyte (NASDAQ:INCY – Free Report) from a strong-buy rating to a buy rating in a report released on Thursday. INCY has been the subject of a number of other research reports. Cantor Fitzgerald initiated coverage on shares of Incyte in a research note on Tuesday, April 23rd. They issued a neutral […]
Incyte (NASDAQ:INCY – Free Report) had its target price cut by BMO Capital Markets from $56.00 to $52.00 in a report issued on Wednesday, Benzinga reports. They currently have a market perform rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on INCY. Oppenheimer dropped their target price on […]
Incyte Co. (NASDAQ:INCY – Get Free Report) shares gapped down before the market opened on Tuesday . The stock had previously closed at $52.56, but opened at $50.40. Incyte shares last traded at $52.10, with a volume of 1,067,639 shares traded. Wall Street Analyst Weigh In Several equities research analysts have commented on the company. […]
First Trust Direct Indexing L.P. raised its stake in Incyte Co. (NASDAQ:INCY – Free Report) by 3.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,454 shares of the biopharmaceutical company’s stock after buying an additional 1,040 shares during the […]